Salt Lake City, UT, April 08, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that the first ...
Recursion announces clinical trial approvals for REC-3565 and REC-4539, targeting B-cell malignancies and small-cell lung cancer. Recursion announced that the UK Medicines and Healthcare Products ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results